CM Management LLC Invests $54,000 in BioCardia, Inc. (NASDAQ:BCDA)

CM Management LLC purchased a new stake in shares of BioCardia, Inc. (NASDAQ:BCDA) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 25,000 shares of the company’s stock, valued at approximately $54,000. CM Management LLC owned approximately 0.55% of BioCardia at the end of the most recent reporting period.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BCDA. HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of BioCardia in a report on Wednesday, December 18th. Alliance Global Partners upgraded shares of BioCardia from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 30th.

Insider Buying and Selling at BioCardia

In other news, Director Simon H. Stertzer purchased 22,753 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were acquired at an average price of $2.30 per share, with a total value of $52,331.90. Following the completion of the purchase, the director now directly owns 40,602 shares of the company’s stock, valued at $93,384.60. The trade was a 127.47 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have bought 26,353 shares of company stock worth $60,585. Insiders own 20.00% of the company’s stock.

BioCardia Price Performance

Shares of BioCardia stock opened at $2.62 on Friday. The firm has a 50 day simple moving average of $2.35 and a 200 day simple moving average of $2.43. BioCardia, Inc. has a fifty-two week low of $1.63 and a fifty-two week high of $6.87. The firm has a market cap of $12.01 million, a P/E ratio of -0.63 and a beta of 1.28.

BioCardia Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.